CCAP
Crescent Capital BDC, Inc.
CCAP's fundamentals are mixed, but it looks expensive: trading at 9.7x earnings, above its usual 7.4x. Analysts expect earnings to decline.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
CCAP Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| N/A | |
| N/A |
CCAP's profitability is currently healthy, but its revenue is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like CCAP.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
CCAP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.8x | $6.07 | -40% |
| Forward | 7x | $10.10 | — |
| Fair | 7.4x | $7.78 | -23% |
| Expensive | 9.4x | $9.89 | -2.1% |
| Current | 9.7x | $10.10 | — |
Historical ranges are pointers, not guarantees.
CCAP's PE is in its expensive range at 9.7x. On analysts' estimates for next year's earnings, today's price would be 7.0x, in its fair range.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
CCAP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Decline | |
| Decline | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect CCAP's earnings and revenue to decline, with profitability weakening.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
IREN has the edge over CCAP on the outlook, with more favorable revenue and profitability expectations.
CCAP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.45 | +38% |
| Q3 2026 | $1.05 | -45% |
| Q2 2026 | $1.23 | -41% |
| Q1 2026 | $1.78 | -20% |
| Q4 2025 | $1.81 | -25% |
| Q3 2025 | $1.91 | -23% |
| Q2 2025 | $2.09 | -14% |
| Q1 2025 | $2.22 | -7.1% |
| Q4 2024 | $2.40 | +4.3% |
CCAP has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
CCAP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $6.6M | -82% |
| Q1 2022 | $23M | -3.1% |
| Q4 2021 | $18.7M | -49% |
| Q3 2021 | $22.9M | -43% |
| Q2 2021 | $35.8M | -38% |
| Q4 2020 | $36.5M | +220% |
IREN has the stronger quarterly revenue trend. Revenue is down 82% for CCAP versus down 5.1% for IREN.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2022 | -9.2% | -104 points |
| Q1 2022 | 71% | -21 points |
| Q4 2021 | 77% | -18 points |
| Q3 2021 | 75% | -21 points |
| Q2 2021 | 95% | -3.4 points |
| Q1 2021 | 92% | N/A |
| Q4 2020 | 96% | +16 points |
| Q3 2020 | 97% | N/A |
CCAP's operating margin was −9.2% last quarter, down 104 points from the same quarter a year ago, near the bottom of its range since 2019.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
CCAP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.4M | -21% |
| Q2 2026 | $9.8M | -73% |
| Q1 2026 | -$23.8M | -$8.7M |
| Q4 2025 | $22.6M | +$25.5M |
| Q3 2025 | $30.8M | -34% |
| Q2 2025 | $36.4M | +$61.1M |
| Q1 2025 | -$15.1M | -138% |
| Q4 2024 | -$2.9M | -108% |
CCAP has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
CCAP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -8.5K shares |
| 1 year | -0.6% | -215K shares |
| 3 years | -0.6% | -216K shares |
| 5 years | +31% | +8.7M shares |
| Available history | +41% | +10.6M shares |
CCAP has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $667,000 |
| Q1 2026 | $1M |
| Q4 2025 | $1M |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
CCAP spent $3M buying back its own shares over the past year.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
CCAP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | 13.4x | High |
| Q1 2022 | 7.6x | High |
| Q4 2021 | 7.1x | High |
| Q3 2021 | 5.1x | High |
| Q2 2021 | 3.8x | Elevated |
| Q1 2021 | 3.2x | Elevated |
| Q4 2020 | 8.5x | High |
| Q3 2020 | 14.2x | High |
CCAP's net debt is about 13 years of its operating earnings (EBITDA), up from 3.8 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CCAP.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
CCAP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.3 | Neutral |
| Stochastic | 34.5 | Neutral |
CCAP's weekly RSI is 45 (neutral) and its Stochastic is 35 (neutral).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
CCAP PE vs Financial Services Sector
| Metric | CCAP | Sector median | Relative |
|---|---|---|---|
| PE | 9.7x | 13x | 26% below |
| PE % | 85 | 65 | 20 pts above |
CCAP is trading at 9.7x earnings, a 26% discount to the Financial Services sector's median of 13x.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
CCAP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.25 | 9.2% above |
| 20 week MA | $10.2 | 0.6% below |
| 50 week MA | $12.0 | 15% below |
| 100 week MA | $14.0 | 28% below |
| 200 week MA | $15.4 | 34% below |
CCAP has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 34% below its 200-week average.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
CCAP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.1 | $15.0 | -12% |
| 2021 | $15.0 | $18.0 | +20% |
| 2022 | $18.0 | $13.1 | -27% |
| 2023 | $13.1 | $17.4 | +32% |
| 2024 | $17.4 | $19.8 | +14% |
| 2025 | $19.8 | $14.7 | -25% |
| 2026 YTD | $14.7 | $10.1 | -31% |
CCAP has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.